Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Vir Biotechnology Inc (VIR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vir Biotech's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.23 +0.60    +7.86%
27/04 - Closed. Currency in USD ( Disclaimer )
After Hours
8.22
-0.01
-0.12%
8:34:32 - Real-time Data
  • Volume: 1,088,640
  • Bid/Ask: 7.87 / 8.45
  • Day's Range: 7.64 - 8.27
Type:  Equity
Market:  United States
Vir Biotech 8.23 +0.60 +7.86%

Vir Biotechnology Inc Company Profile

 
Get an in-depth profile of Vir Biotechnology Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

576

Equity Type

ORD

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Contact Information

Address 1800 Owens Street Suite 900
San Francisco, 94158
United States
Phone 415 906 4324
Fax -

Top Executives

Name Age Since Title
Francis V. Chisari - - Scientific Advisor
Vicki L. Sato 75 2016 Independent Chairman
Phillip A. Sharp 79 2017 Independent Director
George A. Scangos 76 2017 Director
Thomas O. Daniel 70 2017 Scientific Advisor
Jeffrey V. Ravetch 73 - Scientific Advisor
Robert J. Perez 60 2017 Independent Director
Robert J. More 56 2016 Independent Director
Jeffrey A. Bluestone 70 - Scientific Advisor
George H. Poste 80 - Scientific Advisor
Sona Saira Ramasastry 48 2019 Independent Director
Jeffrey S. Hatfield 66 2020 Independent Director
Emilio A. Emini 71 2015 Scientific Advisor
Robert Taylor Nelsen 62 2016 Independent Director
Charles Elliott Sigal 72 2020 Independent Director
Janet Napolitano 66 2020 Independent Director
Charles M. Rice - - Scientific Advisor
Susanna Naggie - - Scientific Advisor
Klaus Frueh 64 2016 Co-Founder & Scientific Advisor
Louis J. Picker - - Co-Founder & Scientific Advisor
Lawrence Corey 76 2016 Co-Founder & Scientific Advisor
Marianne De Backer 55 2023 CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VIR Comments

Write your thoughts about Vir Biotechnology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email